Lupin launched coronavirus drug Favipiravir in India at Rs.49 per tablet

Download our All Government Jobs Android app to get updates on your mobile.

05 August 2020 Current Affairs:Drug major Lupin announced the launch of its Favipiravir drug under the brand name ‘Covihalt.‘ The drug will be used to treat patients with mild to moderate COVID-19 symptoms at Rs.49.  The Drug Controller General of India (DCGI) has approved Favipiravir for emergency use. 

Highlights:
The Covihalt dosage strength has been developed keeping in mind the convenience of administration.
The drug will be available as 200 mg tablets in the form of a strip of 10 tablets and priced at Rs.49 per tablet.
The aim is to leverage the expertise in managing widespread community diseases like tuberculosis (TB) to proactively reach patients across India.
It ensures access to Covihalt through its strong distribution network and field force.
Previously, on August 4, Sun Pharmaceutical Industries had launched Favipiravir under the brand name FluGuard for the treatment of mild to moderate cases of COVID- 19, at Rs.35 per tablet in India. Shares of Lupin were trading 0.32% higher at Rs.943.70 apiece on BSE.

source https://naukri.sarkari-exam.in/lupin-launched-coronavirus-drug-favipiravir-in-india-at-rs-49-per-tablet/

Download our All Government Jobs Android app to get updates on your mobile.